| Title |
Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, January 2018
|
| DOI | 10.1007/s00259-017-3922-y |
| Pubmed ID | |
| Authors |
Philipp Backhaus, Benjamin Noto, Nemanja Avramovic, Lena Sophie Grubert, Sebastian Huss, Martin Bögemann, Lars Stegger, Matthias Weckesser, Michael Schäfers, Kambiz Rahbar |
| Abstract |
Prostate-specific membrane antigen (PSMA) is the up-and-coming target for molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA expression in physiologic tissue as well as in benign and malignant disease has been reported in various publications. Unlike in prostate cancer, PSMA expression is only rarely observed in non-prostate tumor cells. Instead, expression occurs in endothelial cells of tumor-associated neovasculature, although no endothelial expression is observed under physiologic conditions. The resulting potential for tumor staging in non-prostate malignant tumors has been demonstrated in first patient studies. This review summarizes the first clinical studies and deduces future perspectives in staging, molecular characterization, and PSMA-targeted radionuclide therapy based on histopathologic examinations of PSMA expression. The non-exclusivity of PSMA in prostate cancer opens a window to utilize the spectrum of available radioactive PSMA ligands for imaging and molecular characterization and maybe even therapy of non-prostate disease. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Germany | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 97 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 22% |
| Student > Ph. D. Student | 15 | 15% |
| Other | 6 | 6% |
| Student > Bachelor | 6 | 6% |
| Student > Master | 6 | 6% |
| Other | 17 | 18% |
| Unknown | 26 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 45% |
| Chemistry | 7 | 7% |
| Biochemistry, Genetics and Molecular Biology | 5 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Immunology and Microbiology | 2 | 2% |
| Other | 7 | 7% |
| Unknown | 29 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2018.
All research outputs
#15,501,594
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#1,866
of 3,083 outputs
Outputs of similar age
#280,060
of 477,744 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#22
of 42 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 477,744 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.